Every material Form 8-K Karyopharm Therapeutics Inc. has filed with the SEC since November 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on November 2, 2026, and Nasdaq notified the company on November 4 that its common stock will be delisted. The company will not appeal, and the stock is expected to move to an over-the-counter market under the symbol KPTIQ. The filing says the proposed reorganization plan gives common stock and Series A preferred holders no payment, so existing equity is expected to have no value.
Nasdaq trading in common stock suspends at the opening of business on November 11, 2026.
Common stock expected to trade over the counter under the symbol KPTIQ on or after November 11, 2026.
Joint prepackaged Chapter 11 plan filed November 2, 2026 provides no distribution to common or 0% Series A Convertible Perpetual Preferred Stock holders.
The company expects existing equity securities to have no value and holders to face a complete loss.
Karyopharm Therapeutics and its subsidiary KPT Texas LLC filed voluntary Chapter 11 petitions on November 2, 2026, in the U.S. Bankruptcy Court for the Southern District of Texas, after a restructuring support agreement with lenders, noteholders and others. Under the proposed prepackaged plan, the company's existing common stock and Series A Convertible Preferred Stock would be cancelled, and holders would receive no distribution on those shares.
Petition Date was November 2, 2026; the company will operate as a debtor-in-possession under Court supervision.
Ayrmid Ltd. is the stalking horse bidder for a merger with the reorganized company, with bid protections of a 3% break-up fee and expense reimbursement capped at 1% of the Bid Protection Base.
Voting deadline on the prepackaged plan is November 30, 2026; the requested confirmation hearing is on or about January 11, 2027, subject to Court availability.
The Ayrmid term sheet contemplates a new senior secured term loan of up to $135 million, with up to $50 million of New Money DIP Loans to be repaid from its proceeds.
Karyopharm entered a Restructuring Support Agreement with its existing lenders, noteholders and other key stakeholders that provides for a merger with Ayrmid Ltd. To carry it out, the company filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas. The company expects its existing equity securities to have no value, and holders of common stock and Convertible Preferred Stock would receive no payment under the plan.
Voluntary Chapter 11 petitions filed in the U.S. Bankruptcy Court for the Southern District of Texas
Holders of common stock and Convertible Preferred Stock would receive no payment or distribution under the Prepackaged Plan
Up to $55 million in debtor-in-possession financing committed by existing secured lenders, subject to Court approval
Transaction expected to close in the first quarter of 2027; court-supervised bidding procedures allow competing bids
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Karyopharm Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →